Shaanxi Micot Pharmaceutical Technology Co., Ltd. (Ticker: 2335 HK) is a Chinese biotechnology company specializing in the discovery, development and commercialization of bi-/multi-specific peptide drugs for metabolic diseases, as well as cardiovascular and cerebrovascular diseases. Micot Pharma plans to list H shares on the Hong Kong Stock Exchange Main Board on June 24, 2026.

The company is offering 58.05 million shares at an IPO price range of HKD 18.20 to HKD 21.00 per share, raising up to approximately HKD 1.22 billion, or about $156 million. The implied market capitalization is approximately HKD 6.04 billion to HKD 6.97 billion, or around $830 million. Its Core Product, MT1013, is a self-developed Phase III-stage dual-targeting receptor agonist polypeptide mainly designed to treat chronic kidney disease-secondary hyperparathyroidism.

According to published terms, all offered shares are primary shares, with a 15% greenshoe option. IPO proceeds are expected to be used for R&D and product capacity, brand promotion and business development, working capital, strategic acquisitions and other purposes. CCB International Capital and China Merchants Securities (HK) are the sponsors.